Patient demand and politics push Herceptin forward

Kondro, Wayne; Sibbald, Barbara
August 2005
CMAJ: Canadian Medical Association Journal;8/16/2005, Vol. 173 Issue 4, p347
Academic Journal
Reports on the decision of some Canadian provinces to pay for the extended use of trastuzumab or Herceptin in breast cancer treatment in 2005. Percentage of newly diagnosed breast cancer cases who are human epidermal growth factor receptor 2 positive; Number of provinces that have expanded funding for trastuzumab as of July 22, 2005; Comments from Sharon Batt, a breast cancer survivor and a Canadian Institutes of Health Research trainee in the ethics of health research and policy.


Related Articles

  • Trastuzumab emtansine.  // Reactions Weekly;Apr2015, Vol. 1547 Issue 1, p262 

    The article presents a case study of two adult women who developed different toxicities during administration with trastuzumab emtansine for HER2-positive breast cancer.

  • Why HER2 testing is essential. Harmer, Victoria // Cancer Nursing Practice;Dec2007, Vol. 6 Issue 10, p14 

    The article discusses the trastuzumab (Herceptin) to women diagnosed with breast cancer. A trastuzumab is a humanised monoclonal antibody and targets the human epidermal growth factor receptor (HER2) oncoprotein but not associated with chemotherapy. It improves results for all HER2 positive...

  • Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective. Machado, Marcio; Einarson, Thomas R. // Breast Cancer: Targets & Therapy;2012 Part 2, Vol. 4, p173 

    Objective: To evaluate, from the perspective of the Brazilian public health care system, the cost-effectiveness of lapatinib plus capecitabine (LAP/CAP) versus capecitabine alone (CAP) or trastuzumab plus capecitabine (TRAST/CAP) in the treatment of women with human epidermal growth factor...

  • Delays to HER2 test results hinder treatment decisions.  // Cancer Nursing Practice;Nov2008, Vol. 7 Issue 9, p4 

    The article discusses delays in test results for women with early stage HER2-positive breast cancer. According to the article, only about a quarter of 200 clinicians said that HER2 test results are available at multidisciplinary meetings, where healthcare professionals make decisions about...

  • Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. Tovey, S. M.; Brown, S.; Doughty, J. C.; Mallon, E. A.; Cooke, T. G.; Edwards, J. // British Journal of Cancer;3/10/2009, Vol. 100 Issue 5, p680 

    We present a retrospective analysis on a cohort of low-grade, node-negative patients showing that human epidermal growth factor receptor 2 (HER2) status significantly affects the survival in this otherwise very good prognostic group. Our results provide support for the use of adjuvant...

  • A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Hudis, Clifford; Swanton, Charles; Janjigian, Yelena Y.; Lee, Ray; Sutherland, Stephanie; Lehman, Robert; Chandarlapaty, Sarat; Hamilton, Nicola; Gajria, Devika; Knowles, James; Shah, Jigna; Shannon, Keith; Tetteh, Ernestina; Sullivan, Daniel M.; Moreno, Carolina; Yan, Li; Han, Hyo Sook // Breast Cancer Research;2013, Vol. 15 Issue 6, p3 

    The article presents a study which investigates the effects of combining the trastuzumab and an allosteric AKT inhibitor MK-2206 in treating patients with human epidermal growth factor receptor 2 (HER2)-positive breast and gastric cancers. The study was conducted to determine the safety and...

  • Dodging a dogma: is treating beyond progression beneficial? Naing, Aung; Kurzrock, Razelle // Cancer Chemotherapy & Pharmacology;May2013, Vol. 71 Issue 5, p1385 

    No abstract available.

  • HER2 Therapy � An Abundance of Riches. Gradishar, William J. // New England Journal of Medicine;1/12/2012, Vol. 366 Issue 2, p176 

    The article discusses the results of the Clinical Evaluation of Pertuzumab and Trastuzumab clinical trial. This randomized trial in patients focused on the use of first-line therapy with trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2 (HER2)-positive breast...

  • Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. Slamon, Dennis J.; Leyland-Jones, Brian; Shak, Steven; Fuchs, Hank; Paton, Virginia; Bajamonde, Alex; Fleming, Thomas; Eiermann, Wolfgang; Wolter, Janet; Pegram, Mark; Baselga, Jose; Norton, Larry // New England Journal of Medicine;03/15/2001, Vol. 344 Issue 11, p783 

    Background: The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the aggressiveness of the tumor. Methods: We evaluated the efficacy and safety of trastuzumab, a recombinant monoclonal antibody...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics